Rebecca E Graff1, Sören Möller2, Michael N Passarelli3, John S Witte4, Axel Skytthe2, Kaare Christensen2, Qihua Tan2, Hans-Olov Adami5, Kamila Czene6, Jennifer R Harris7, Eero Pukkala8, Jaakko Kaprio9, Edward L Giovannucci10, Lorelei A Mucci11, Jacob B Hjelmborg2. 1. Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California. Electronic address: Rebecca.Graff@ucsf.edu. 2. Epidemiology, Biostatistics and Biodemography, Department of Public Health, University of Southern Denmark, Denmark; The Danish Twin Registry, University of Southern Denmark, Denmark. 3. Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California. 4. Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California; Institute for Human Genetics, University of California San Francisco, San Francisco, California; Department of Urology, University of California San Francisco, San Francisco, California; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California. 5. Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. 6. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. 7. Department of Genetics and Bioinformatics, Norwegian Institute of Public Health, Oslo, Norway. 8. Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland; School of Health Sciences, University of Tampere, Tampere, Finland. 9. Department of Public Health, University of Helsinki, Helsinki, Finland; National Institute for Health and Welfare, Department of Health, Helsinki, Finland; Institute for Molecular Medicine Finland, Helsinki, Finland. 10. Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts; Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 11. Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts; Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Centre for Public Health Sciences, University of Iceland, Reykjavik, Iceland.
Abstract
BACKGROUND & AIMS: We analyzed data from twins to determine how much the familial risk of colorectal cancer can be attributed to genetic factors vs environment. We also examined whether heritability is distinct for colon vs rectal cancer, given evidence of distinct etiologies. METHODS: Our data set included 39,990 monozygotic and 61,443 same-sex dizygotic twins from the Nordic Twin Study of Cancer. We compared each cancer's risk in twins of affected co-twins relative to the cohort risk (familial risk ratio [FRR]). We then estimated the proportion of variation in risk that could be attributed to genetic factors (heritability). RESULTS: From earliest registration in 1943 through 2010, there were 1861 individuals diagnosed with colon cancer and 1268 diagnosed with rectal cancer. Monozygotic twins of affected co-twins had an FRR for colorectal cancer of 3.1 (95% confidence interval [CI], 2.4-3.8) relative to the cohort risk. Dizygotic twins of affected co-twins had an FRR for colorectal cancer of 2.2 (95% CI, 1.7-2.7). We estimated that 40% (95% CI, 33%-48%) of the variation in colorectal cancer risk could be attributed to genetic factors; unique environment only accounted for the remaining liability. For colon cancer, the FRR was 3.3 (95% CI, 2.1-4.5) for monozygotic twins and 2.6 (95% CI, 1.7-3.5) for dizygotic twins. For rectal cancer, comparable estimates were 3.3 (95% CI, 1.5-5.1) for monozygotic twins and 2.6 (95% CI, 1.2-4.0) for dizygotic twins. Heritability estimates for colon and rectal cancer were 16% (95% CI, 0-46%) and 15% (95% CI, 0-50%), common environment estimates were 15% (95% CI, 0-38%) and 11% (95% CI, 0-38%), and unique environment estimates were 68% (95% CI, 57%-79%) and 75% (95% CI, 61%-88%), respectively. CONCLUSIONS: Interindividual genetic differences could account for 40% of the variation in susceptibility to colorectal cancer; risk for colon and rectal cancers might have less of a genetic component than risk for colorectal cancer. Siblings, and particularly monozygotic co-twins, of individuals with colon or rectal cancer should consider personalized screening.
BACKGROUND & AIMS: We analyzed data from twins to determine how much the familial risk of colorectal cancer can be attributed to genetic factors vs environment. We also examined whether heritability is distinct for colon vs rectal cancer, given evidence of distinct etiologies. METHODS: Our data set included 39,990 monozygotic and 61,443 same-sex dizygotic twins from the Nordic Twin Study of Cancer. We compared each cancer's risk in twins of affected co-twins relative to the cohort risk (familial risk ratio [FRR]). We then estimated the proportion of variation in risk that could be attributed to genetic factors (heritability). RESULTS: From earliest registration in 1943 through 2010, there were 1861 individuals diagnosed with colon cancer and 1268 diagnosed with rectal cancer. Monozygotic twins of affected co-twins had an FRR for colorectal cancer of 3.1 (95% confidence interval [CI], 2.4-3.8) relative to the cohort risk. Dizygotic twins of affected co-twins had an FRR for colorectal cancer of 2.2 (95% CI, 1.7-2.7). We estimated that 40% (95% CI, 33%-48%) of the variation in colorectal cancer risk could be attributed to genetic factors; unique environment only accounted for the remaining liability. For colon cancer, the FRR was 3.3 (95% CI, 2.1-4.5) for monozygotic twins and 2.6 (95% CI, 1.7-3.5) for dizygotic twins. For rectal cancer, comparable estimates were 3.3 (95% CI, 1.5-5.1) for monozygotic twins and 2.6 (95% CI, 1.2-4.0) for dizygotic twins. Heritability estimates for colon and rectal cancer were 16% (95% CI, 0-46%) and 15% (95% CI, 0-50%), common environment estimates were 15% (95% CI, 0-38%) and 11% (95% CI, 0-38%), and unique environment estimates were 68% (95% CI, 57%-79%) and 75% (95% CI, 61%-88%), respectively. CONCLUSIONS: Interindividual genetic differences could account for 40% of the variation in susceptibility to colorectal cancer; risk for colon and rectal cancers might have less of a genetic component than risk for colorectal cancer. Siblings, and particularly monozygotic co-twins, of individuals with colon or rectal cancer should consider personalized screening.
Authors: Wade S Samowitz; Hans Albertsen; Jennifer Herrick; Theodore R Levin; Carol Sweeney; Maureen A Murtaugh; Roger K Wolff; Martha L Slattery Journal: Gastroenterology Date: 2005-09 Impact factor: 22.682
Authors: P Lichtenstein; N V Holm; P K Verkasalo; A Iliadou; J Kaprio; M Koskenvuo; E Pukkala; A Skytthe; K Hemminki Journal: N Engl J Med Date: 2000-07-13 Impact factor: 91.245
Authors: Stephanie L Schmit; Fredrick R Schumacher; Christopher K Edlund; David V Conti; Ugonna Ihenacho; Peggy Wan; David Van Den Berg; Graham Casey; Barbara K Fortini; Heinz-Josef Lenz; Teresa Tusié-Luna; Carlos A Aguilar-Salinas; Hortensia Moreno-Macías; Alicia Huerta-Chagoya; María Luisa Ordóñez-Sánchez; Rosario Rodríguez-Guillén; Ivette Cruz-Bautista; Maribel Rodríguez-Torres; Linda Liliana Muñóz-Hernández; Olimpia Arellano-Campos; Donají Gómez; Ulices Alvirde; Clicerio González-Villalpando; María Elena González-Villalpando; Loic Le Marchand; Christopher A Haiman; Jane C Figueiredo Journal: Carcinogenesis Date: 2016-04-18 Impact factor: 4.944
Authors: Anna N Wilkinson; David Lieberman; Grigorios I Leontiadis; Frances Tse; Alan N Barkun; Ahmed Abou-Setta; John K Marshall; Jewel Samadder; Harminder Singh; Jennifer J Telford; Jill Tinmouth; Desmond Leddin Journal: Can Fam Physician Date: 2019-11 Impact factor: 3.275
Authors: Bradley T Harris; Vidya Rajasekaran; James P Blackmur; Alan O'Callaghan; Kevin Donnelly; Maria Timofeeva; Peter G Vaughan-Shaw; Farhat V N Din; Malcolm G Dunlop; Susan M Farrington Journal: Sci Rep Date: 2022-08-10 Impact factor: 4.996
Authors: Tomas Tanskanen; Linda van den Berg; Niko Välimäki; Mervi Aavikko; Eivind Ness-Jensen; Kristian Hveem; Yvonne Wettergren; Elinor Bexe Lindskog; Neeme Tõnisson; Andres Metspalu; Kaisa Silander; Giulia Orlando; Philip J Law; Sari Tuupanen; Alexandra E Gylfe; Ulrika A Hänninen; Tatiana Cajuso; Johanna Kondelin; Antti-Pekka Sarin; Eero Pukkala; Pekka Jousilahti; Veikko Salomaa; Samuli Ripatti; Aarno Palotie; Heikki Järvinen; Laura Renkonen-Sinisalo; Anna Lepistö; Jan Böhm; Jukka-Pekka Mecklin; Nada A Al-Tassan; Claire Palles; Lynn Martin; Ella Barclay; Albert Tenesa; Susan M Farrington; Maria N Timofeeva; Brian F Meyer; Salma M Wakil; Harry Campbell; Christopher G Smith; Shelley Idziaszczyk; Tim S Maughan; Richard Kaplan; Rachel Kerr; David Kerr; Daniel D Buchanan; Aung K Win; John Hopper; Mark A Jenkins; Polly A Newcomb; Steve Gallinger; David Conti; Fredrick R Schumacher; Graham Casey; Jeremy P Cheadle; Malcolm G Dunlop; Ian P Tomlinson; Richard S Houlston; Kimmo Palin; Lauri A Aaltonen Journal: Int J Cancer Date: 2017-10-12 Impact factor: 7.396
Authors: Kevin J Monahan; Nicola Bradshaw; Sunil Dolwani; Bianca Desouza; Malcolm G Dunlop; James E East; Mohammad Ilyas; Asha Kaur; Fiona Lalloo; Andrew Latchford; Matthew D Rutter; Ian Tomlinson; Huw J W Thomas; James Hill Journal: Gut Date: 2019-11-28 Impact factor: 23.059